Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Intravenous (IV) ketamine is effective in adults resistant to depression. The response was similar to that seen in younger patients, two new studies show.
Read Full NewsTake 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.
Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.
A study reveals EEG and MRI biomarkers in MOGAD patients with epilepsy, highlighting potential early indicators for refractory epilepsy and improved treatment outcomes.
Despite the availability of antiseizure medications approved for Dravet syndrome, a recent survey presented at AES 2025 showed that these therapies remain underutilized in patients.
Serum Albumin Levels Can Predict Increased Cancer Risk in Hemodialysis
1.
Watch for Psoriasis After Cancer Immunotherapy, Study Says
2.
Prostate cancer early detection system eliminates need for biopsy.
3.
AI tool identifies women at high risk of interval breast cancer
4.
Two medications might work better for breast cancers that are resistant to one.
5.
Citing a cancer risk, the EPA sets a new limit on medical sterilization chemicals.
1.
The Latest Research on Basal Cell Carcinoma: New Developments in Diagnosis and Cure
2.
Therapeutic Innovations Through Germline Predisposition in Acute Leukemias and Myeloid Neoplasms
3.
Revolutionizing Cancer Care with Fulphila: A New Hope for Patients
4.
Advancements in Cancer Treatment and Survival Outcomes for Acute Myeloid Leukemia
5.
Neuroendocrine Tumors: Case Study on Diagnosis, Treatment Strategies & Patient Management
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
2.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
3.
Oropharyngeal Cancer in Relation to HPV Status
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge